• Alias: BMS-582664
    • The alaninate salt of a VEGFR2 inhibitor that strongly binds to and inhibits VEGFR2 and FGFR tyrosine kinases
    • Currently in phase 3 trials for HCC; phase 2 trials under way for colorectal cancer, pancreatic cancer, NSCLC, gastric and GE junction cancer, pancreatic cancer, bladder cancer, and STS
    • Recommended phase 2 dose: 800 mg PO daily
    • Half-life: â™13.8 hours
    • Common side effects: Nausea/vomiting, diarrhea, constipation, fatigue
    (Mekhail et al., 2010)
    Other topics in Targeted and Immunotherapy Agents